ALFA FinderBSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,161.00
- Market cap
- ₹5,347 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 40.1×Sector 43.0×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other promoter buying (off-market) announcements
All →Amanta Healthcare Promoter Buying (Off-Market): ₹5.4 Cr
Promoter Jitendrakumar Patel bought 3,00,150 Amanta Healthcare shares off-market for about Rs 5.40 Crore. Promoter holding rises from 9.02% to 9.79%.
- Value
- ₹5.40 Cr
- Promoter stake change
- +0.77%
Advit Jewels Promoter Buying (Off-Market)
Abhishek Gilara received 77.78 lakh Advit Jewels shares from brother Vipul Gilara via an inter-se gift. The acquirer's holding rises to 16.98%, with no consideration paid.
- Promoter stake change
- +16.98%
Axita Cotton Promoter Buying (Off-Market)
Gitaben Patel, a promoter group member, will acquire 3,98,70,411 Axita Cotton shares (10.42%) as a gift from relative Kushal Patel. Her stake rises from 3.33% to 13.75%.
- Promoter stake change
- +10.42%
Jindal Hotels Promoter Buying (Off-Market)
Piyush D. Shah, promoter and MD of Jindal Hotels, acquired 1,31,368 shares (1.88%) by way of gift on 04.11.2026, raising his holding to 19%. The filing is a Reg 29(2) SAST disclosure of an off-market promoter transfer.
- Promoter stake change
- +1.88%
AVI Products India Promoter Buying (Off-Market)
PPMS Real Estates LLP, AVI Products' promoter, shifted partner stakes internally; Parthh Mehta fell from 99% to 96.76%. Its 62.83% direct holding in AVI is unchanged.
Inox India Promoter Buying (Off-Market)
Shreyasi Goenka disclosed a Reg 10(1)(a)(i) inter-se gift of 18,18,449 INOX India shares (2.00%) from Pavan Kumar Jain, with no consideration. The transfer is among immediate promoter relatives, so no open offer is triggered.
- Promoter stake change
- +2.00%